The estimated Net Worth of David Pernock is at least $3.18 Milion dollars as of 19 May 2017. Mr. Pernock owns over 255 units of Eagle Pharmaceuticals Inc stock worth over $3,603 and over the last 14 years he sold EGRX stock worth over $0. In addition, he makes $3,172,420 as President a Chief Operating Officer at Eagle Pharmaceuticals Inc.
Sign up
Mr. Pernock EGRX stock SEC Form 4 insiders trading
David has made over 14 trades of the Eagle Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 255 units of EGRX stock worth $20,321 on 19 May 2017.
The largest trade he's ever made was buying 50,000 units of Eagle Pharmaceuticals Inc stock on 2 December 2016 worth over $46,000. On average, David trades about 3,647 units every 41 days since 2011. As of 19 May 2017 he still owns at least 966 units of Eagle Pharmaceuticals Inc stock.
You can see the complete history of Mr. Pernock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Pernock biography
David M. Pernock serves as President, Chief Operating Officer of the Company. Previously, Mr. Pernock served as a member of our Board from April 2015 until January 2017. Before becoming our President and Chief Commercial Officer in January 2017, Mr. Pernock served as chairman of the board of directors since September 2009 and as chief executive officer since February 2010 of Fibrocell Science, Inc., a publicly-traded autologous cell and gene therapy company. From December 1993 until November 2009, Mr. Pernock held various positions at GlaxoSmithKline, eventually serving as senior vice president of pharmaceuticals, vaccines (biologics), oncology, acute care, and HIV divisions. From May 2009 until February 2011, Mr. Pernock served as a director of Martek Biosciences Corporation. Mr. Pernock holds a B.S. in business administration from Arizona State University.
What is the salary of David Pernock?
As the President a Chief Operating Officer of Eagle Pharmaceuticals Inc, the total compensation of David Pernock at Eagle Pharmaceuticals Inc is $3,172,420. There are 1 executives at Eagle Pharmaceuticals Inc getting paid more, with Scott Tarriff having the highest compensation of $7,883,700.
How old is David Pernock?
David Pernock is 65, he's been the President a Chief Operating Officer of Eagle Pharmaceuticals Inc since 2018. There are 2 older and 8 younger executives at Eagle Pharmaceuticals Inc. The oldest executive at Eagle Pharmaceuticals Inc is Steven Ratoff, 77, who is the Independent Director.
What's David Pernock's mailing address?
David's mailing address filed with the SEC is EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE, NJ, 07677.
Insiders trading at Eagle Pharmaceuticals Inc
Over the last 11 years, insiders at Eagle Pharmaceuticals Inc have traded over $188,911,314 worth of Eagle Pharmaceuticals Inc stock and bought 1,029,065 units worth $16,655,732 . The most active insiders traders include Executive Capital Lphec Man..., Douglas L Braunstein a Investments Iv, L.P.Pro Que.... On average, Eagle Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $193,721. The most recent stock trade was executed by Scott Tarriff on 1 November 2023, trading 21,619 units of EGRX stock currently worth $299,207.
What does Eagle Pharmaceuticals Inc's logo look like?
Complete history of Mr. Pernock stock trades at Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals Inc executives and stock owners
Eagle Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Scott Tarriff,
Chief Executive Officer, Director -
David Pernock,
President, Chief Operating Officer -
David M. Pernock,
Exec. VP of Operations -
Brian Joseph Cahill,
Chief Financial Officer -
Michael Graves,
Independent Chairman of the Board -
Steven Ratoff,
Independent Director -
Robert Glenning,
Independent Director -
Jennifer Simpson,
Independent Director -
Richard Edlin,
Independent Director -
Lisa Wilson,
IR Contact Officer -
Brian Cahill,
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer -
Debra M. Hussain,
Sr. VP & Head of Commercial -
Reiner Nowak,
Exec. -
Dr. Gaozhong Zhu Ph.D.,
Sr. VP of Pharmaceutical Devel. -
Dr. Valentin R. Curt M.D.,
Sr. VP of Clinical Drug Devel. -
John Kimmet,
Exec. VP of Marketing Oncology & Acute Care -
Michael Shawn Moran,
Exec. VP, Chief Commercial Officer & Principal Operating Officer -
Daniel O'Connor,
Exec. VP, Chief Strategy Officer & Head of Corp. Devel. -
Ryan Debski,
Exec. VP, Gen. Counsel & Chief Compliance Officer -
Steven L. Krill,
Chief Scientific Officer -
Pete A. Meyers,
Chief Financial Officer -
David E Riggs,
Chief Financial Officer -
Investments Iv, L.P.Pro Que...,
-
Sander A Flaum,
Director -
Douglas L Braunstein,
Director -
Executive Capital Lphec Man...,
-
Alain Schreiber,
Director -
Jay Moorin,
Director -
Management Llc Pro Quest In...,
-
Financial Llc Pro Quest Inv...,
-
Paul Bruinenberg,
Chief Medical Officer -
Associates Iv Llc Pro Quest...,
-
Judith Ng Cashin,
Chief Medical Officer -
Luciana Borio,
Director -
Michael Shawn Moran,
EVP, Chief Commercial Officer